What do systematic reviews say?

Recombinant human C1 esterase inhibitor vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Recombinant human C1 esterase inhibitor vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Recombinant human C1 esterase inhibitor vs placebo or active control

Recombinant human C1 esterase inhibitor showed no clear difference in adverse events(during compared with placebo or active control (low certainty).

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  RR 1.39 [0.71, 2.7]
  1 study · 29 participants
  Low

Lanadelumab vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Lanadelumab vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 83 participants
  Low

Lanadelumab vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Lanadelumab vs placebo or active control

Lanadelumab showed no clear difference in serious adverse events (during compared with placebo or active control (low certainty).

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  RR 0.88 [0.08, 10.39]
  2 studies · 162 participants
  Low

Lanadelumab vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 68 participants
  Low

Lanadelumab vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 64 participants
  Low

Lanadelumab vs placebo or active control

Lanadelumab showed no clear difference in adverse events(during compared with placebo or active control (low certainty).

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  RR 1.07 [0.77, 1.47]
  2 studies · 158 participants
  Low

Avoralstat vs placebo

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 93 participants
  Moderate

Avoralstat vs placebo

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Avoralstat vs placebo

Avoralstat showed no clear difference in adverse events (during compared with placebo (low certainty).

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  RR 0.85 [0.62, 1.16]
  1 study · 24 participants
  Low

Berotralstat vs placebo or active control

Berotralstat showed no clear difference in risk of HAE attacks (during compared with placebo or active control (low certainty).

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  RR 0.63 [0.39, 1]
  1 study · 37 participants
  Low

Berotralstat vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 130 participants
  Low

Intervention not reported

• Heparin‐bonded catheters for prolonging the patency of central venous catheters in children 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 200 participants
  Low

Intervention not reported

The intervention showed no clear difference in catheter‐related thrombosis at any time during catheter stay (moderate certainty).

• Heparin‐bonded catheters for prolonging the patency of central venous catheters in children 2014 · Cochrane Headline outcomes only
  RR 0.34 [0.01, 7.68]
  2 studies · 287 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in occlusion of catheter within one week of catheter insertion (low certainty).

• Heparin‐bonded catheters for prolonging the patency of central venous catheters in children 2014 · Cochrane Headline outcomes only
  RR 0.06 [0, 1.07]
  1 study · 200 participants
  Low

Intervention not reported

The intervention may leads to lower catheter‐related blood stream infection and CVC‐related colonization (low certainty).

• Heparin‐bonded catheters for prolonging the patency of central venous catheters in children 2014 · Cochrane Headline outcomes only
  RR 0.06 [0.01, 0.41]
  1 study · 200 participants
  Low

Intervention not reported

The intervention showed no clear difference in side effects: Thrombocytopenia after catheter insertion (low certainty).

• Heparin‐bonded catheters for prolonging the patency of central venous catheters in children 2014 · Cochrane Headline outcomes only
  RR 0.73 [0.38, 1.39]
  2 studies · 287 participants
  Low